Eisai Co Ltd
TSE:4523

Watchlist Manager
Eisai Co Ltd Logo
Eisai Co Ltd
TSE:4523
Watchlist
Price: 4 258 JPY -0.35% Market Closed
Market Cap: 1.2T JPY
Have any thoughts about
Eisai Co Ltd?
Write Note

Eisai Co Ltd
Investor Relations

Eisai Co., Ltd., established in 1941, has emerged as a formidable player in the global pharmaceutical landscape, forging its reputation through a steadfast commitment to "human health care" (hhc). Rooted in Tokyo, the company orbits around the development of innovative treatments targeting neurology and oncology, positioning itself as a beacon of hope for patients worldwide. Eisai's journey is characterized by a persistent focus on medicinal breakthroughs in areas such as Alzheimer’s disease, liver cancer, and epilepsy—disease states that critically affect the quality of life but often have limited treatment options. Through its rigorous research and development efforts, the company crafts both small molecule drugs and biologics, distinguishing itself with flagship products like Aricept for Alzheimer's and Lenvima for cancer, both of which have cemented its reputation in the medical community and are vital streams of revenue.

Eisai's business framework is intricately woven into a global tapestry of partnerships and collaborations, which amplifies its market reach and bolsters its financial performance. By strategically aligning with global pharmaceutical giants and leveraging robust patent portfolios, Eisai extends its innovative therapies to numerous markets. This strategic network allows it to not only enhance drug distribution and sales but also to engage in co-development, introducing shared stewardship in groundbreaking research. The company's financial structure is further reinforced through a diversified portfolio, inclusive of both branded prescription drugs and over-the-counter products, thus facilitating consistent cash flow and enabling ongoing investments in research. These deliberate steps underscore Eisai's pursuit of longevity in a fiercely competitive industry, ensuring it remains well-poised to continually adapt and thrive amidst evolving healthcare challenges.

Show more

Earnings Calls

Show Transcript
Previous
Next
Loading

Management

Mr. Haruo Naito
CEO, Representative Corporate Officer & Director
No Bio Available
Mr. Gary Hendler
Senior VP & President of EMEA Region
No Bio Available
Dr. Lynn D. Kramer FAAN, M.D.
VP & Chief Clinical Officer
No Bio Available
Ms. Yanhui Feng
Senior Vice President
No Bio Available
Mitsuru Shomon
VP & CFO
No Bio Available
Mr. Keisuke Naito
Representative Corporate Officer, EVP, COO & Chief Growth Officer
No Bio Available
Makoto Hoketsu
VP & Chief Information Officer
No Bio Available
Mr. Masatomi Akana
Senior VP, Chief Government Relations Officer & Chief IR Officer
No Bio Available
Shin Kato
VP, General Counsel & Chief Compliance Officer
No Bio Available
Ms. Sayoko Sasaki
Vice President of Corporate Communications & Sustainability
No Bio Available

Contacts

Address
TOKYO-TO
Bunkyo-ku
Eisai Main Bldg., 4-6-10, Koishikawa
Contacts
+81338173700.0
www.eisai.co.jp